Profil bibliographique

Dina Schneider

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

131Publications signalées

3415Citations signalées

2Affiliations récentes

Institutions déclarées

Lentigen Technology (United States)Cara Therapeutics (United States)

Domaines associés

CAR-T cell therapy researchViral Infectious Diseases and Gene Expression in InsectsBiosimilars and Bioanalytical MethodsVirus-based gene therapy researchImmune Cell Function and Interaction

Publications récentes

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Clinical Protocol 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Data from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

Sumithira Vasu, Nathan Denlinger, No‐Joon Song, Danielle Elsberry et autres

0 citations

Accès ouvert 2026 articleOpenAlex

Optimized tandem BCMA-specific CAR T-cells designed to minimize tonic signaling and off-target toxicity

Xu Wang, Peirong Hu, Brittany Steimle, Michael Wagner et autres

0 citationsBlood Immunology & Cellular Therapy

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.